Analyzing the most frequent disease loci in targeted patient categories optimizes disease gene identification and test accuracy worldwide by unknown
Lebo and Tonk Journal of Translational Medicine  (2015) 13:16 
DOI 10.1186/s12967-014-0333-8RESEARCH Open AccessAnalyzing the most frequent disease loci in
targeted patient categories optimizes disease
gene identification and test accuracy worldwide
Roger V Lebo1,2* and Vijay S Tonk3,4Abstract
Background: Our genomewide studies support targeted testing the most frequent genetic diseases by patient
category: (1) pregnant patients, (2) at-risk conceptuses, (3) affected children, and (4) abnormal adults. This approach
not only identifies most reported disease causing sequences accurately, but also minimizes incorrectly identified
additional disease causing loci.
Methods: Diseases were grouped in descending order of occurrence from four data sets: (1) GeneTests 534 listed
population prevalences, (2) 4129 high risk prenatal karyotypes, (3) 1265 affected patient microarrays, and (4)
reanalysis of 25,452 asymptomatic patient results screened prenatally for 108 genetic diseases. These most frequent
diseases are categorized by transmission: (A) autosomal recessive, (B) X-linked, (C) autosomal dominant, (D) microscopic
chromosome rearrangements, (E) submicroscopic copy number changes, and (F) frequent ethnic diseases.
Results: Among affected and carrier patients worldwide, most reported mutant genes would be identified correctly
according to one of four patient categories from at-risk couples with <64 tested genes to affected adults with 314
tested loci. Three clinically reported patient series confirmed this approach. First, only 54 targeted chromosomal sites
would have detected all 938 microscopically visible unbalanced karyotypes among 4129 karyotyped POC, CVS,
and amniocentesis samples. Second, 37 of 48 reported aneuploid regions were found among our 1265 clinical
microarrays confirming the locations of 8 schizophrenia loci and 20 aneuploidies altering intellectual ability, while
also identifying 9 of the most frequent deletion syndromes. Third, testing 15 frequent genes would have identified 124
couples with a 1 in 4 risk of a fetus with a recessive disease compared to the 127 couples identified by
testing all 108 genes, while testing all mutations in 15 genes could have identified more couples.
Conclusion: Testing the most frequent disease causing abnormalities in 1 of 8 reported disease loci [~1 of 84 total
genes] will identify ~7 of 8 reported abnormal Caucasian newborn genotypes. This would eliminate ~8 to 10 of ~10
Caucasian newborn gene sequences selected as abnormal that are actually normal variants identified when
testing all ~2500 diseases looking for the remaining 1 of 8 disease causing genes. This approach enables more
accurate testing within available laboratory and reimbursement resources.
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Targeted testing the most frequent listed disease causing
sites comprising <0.3% to 1.5% [This study] of the
~22,000 individual gene locations causing ~2500 total
reported diseases [1] will minimize the number of incor-
rectly identified abnormal gene sequences by excluding
nearly all normally variant sequences. By minimizing in-
terpretation time and confirmation of abnormal results,
this will enableready identification of most disease caus-
ing genomic sequences to expedite patient testing.
All laboratory tests have limitations. Because positive
genetic test results may provide the basis for clinical de-
cisions on both patients and their relatives for many
years, clinical laboratories continually strive to offer op-
timal tests that maintain the highest possible reported
accuracy. Genomewide analysis is limited by genome
complexity so that accurate interpretation of all test re-
sults can be challenging. For instance, genomewide
microarray analysis of 1,800,000 sites for disease causing
rearrangements also identifies 906,600 polymorphisms
and 5,677 copy number variants [2] among the
~2,370,000 total listed copy number variants [3]. Geno-
mewide next generation sequencing continues to identify
reported genetic mutations with ever more accurate,
rapid, less expensive platforms that can analyze a few se-
lected genes up to all ~22,000 genes in the 6,000,000,000
basepair diploid genome. Yet the more sites tested, the
more normal sites are identified as abnormal by available
data analysis. Currently “the rate limiting factor in clin-
ical genomewide testing is the numerous variant gene
sequences that multiply the cost of interpreting the raw
sequence about 10-fold” [4].
Dr. James Watson, a healthy senior scientist was
among the first three individuals to have his entire gen-
ome sequenced [5,6]. Three computer programs found
Dr. Watson’s genome includes (1) two homozygous vari-
ants in genes previously reported to cause Usher Syn-
drome 1b and Cockayne syndrome, both early childhood
diseases [7], and (2) a breast cancer gene sequence ori-
ginally interpreted to reflect a major mutation among
his >80 described mutated alleles. Subsequent reinter-
pretation of his known breast cancer gene variant
avoided further clinical intervention [6]. None of these
three diseases are among the most frequent selected for
routine genomewide testing (Additional file 1: Table S1,
Additional file 2: Table S2, Additional file 3: Table S3,
Table 1).
Carrier screening for cystic fibrosis has been applied
to millions of patients and their at-risk partners accord-
ing to this current standard-of-care DNA test [8,9] re-
ported as either positive or with a residual negative test
risk [10,11]. Newborn Screening Programs in every state
test for selected abnormal metabolite concentrations by
mass spec while some states also test newborns forcystic fibrosis mutations to optimize follow up care.
[Additional file 1: Table S1A, Column 2, NB tested in
Ohio] Frequent disease gene mutation screening selected
for Ashkenazi patients by ACMG [12] and completed on
tens of thousands of Ashkenazi patients from New York
to Tel Aviv [13] is attributed with substantially reducing
the frequency of affected newborns with these ethnic
diseases.
Platforms that sequence the exome and those that
quantify the copy number of targeted sites [14-16] to-
gether enable genomewide analysis to identify (1) single
nucleotide substitutions, (2) gene deletions revealed by
FISH, and (3) unbalanced chromosome region copy
number abnormalities identified by karyotypes and pre-
cisely delineated by microarrays. Standard karyotyping is
still the preferred method for detecting balanced and
complex rearrangements, as microarray and sequencing
methods are being validated to detect balanced abnor-
malities ([17], Results). Additional modifications to DNA
analysis platforms have enabled sequencing single nu-
cleotide mutations by microarrays [18] while other com-
puter programs count and list the number of copies of
each selected sequenced locus to quantify abnormal gen-
omic sites c.f. [19].
Targeting genomewide screening the most frequent
genetic diseases affecting the largest proportion of
patients worldwide with rapid analysis platforms will
enable unambiguously identifying more abnormal geno-
types in at-risk couples and affected conceptuses and pa-
tients with fewer confounding results [Tables 1 and 2].
Testing products of conception and fetuses for the most
frequent chromosome aneuploidies identifies the largest
proportion of abnormal conceptuses [Additional file 2:
Table S2, Col 2,3,4]. Testing abnormal infants and chil-
dren identifies a substantial proportion of patients with
altered intellectual development caused by a frequently
deleted or duplicated submicroscopic chromosome re-
gion (Additional file 3: Table S3). Simultaneously testing
for the other most frequent dominant and recessive sin-
gle gene disorders including those in appropriate ethnic
populations [Additional file 1: Table S1F] can provide ac-
curate results to large patient populations within med-
ical, laboratory, and reimbursement resources [Table 1].
Methods
Design of the study
This study tested the hypothesis that analyzing the most
frequent genetic diseases selected from all reported dis-
eases would identify the largest proportion of disease
causing mutations to unambiguously define each positive
testing patient’s genetic abnormality with very few incor-
rect test results. For instance, when testing 100,000 pa-
tients for the frequent autosomal recessive cystic fibrosis
mutations with 99.9% test accuracy per gene, a positive
Table 1 Total population frequencies (Additional file 1: Table S1A, B, C, D3, E right) by selected tested patient
categories (Additional file 1: Table S1D1, D2, E2)
Note: These frequencies will be substantially higher for symtomatic patients
Disease categories Caucasian Worldwide+
Tested (a) Affected (b) Heterozygote (a’) Affected (b’) Heterozygote
1. COUPLES, Asymptomatic, at risk ~1/132 ~1/174
(1A2b +1B2b) (ASYMPTOMATIC, (~.76%) (~.58%)
2. FETUSES, Abnormal ~1/11.0 (1/11.1)
(1A1a +1 B1a +2A1 + 3A) (~9.2%) (~9.0%)
3. NEWBORNS, Affected ~1/52 ~1/54
(1A1a + 1B1a + 1Ca + 2c + 3A) ~1.91% ~1.86%
4. ADULTS(a), Affected ~1/37 ~1/43
(1A1a,1B1a + 1Ca +1 Da +2A +3A) ~2.71% ~2.33%
Testing for Abnormal Genotypes in Asymptomatic Adults and Symptomatic Fetuses, Newborns, Children, and Adults.
Frequencies for each disease category are listed in Additional file 1: Table S1 according to the frequency in the general population. Clinically affected patients tested for
any age-appropriate category carry substantially greater frequencies of affected genotypes (Additional file 2: Table S2 and Additional file 3: Table S3). Age appropriate
tests are anticipated to optimally identify specific diseases in affected patients according to patient category (Table 4).
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incorrect answers (Table 3, top; Ref. [20]). In contrast,
when testing the rare fumarase deficiency gene locus
with the same test accuracy, a positive carrier test would
not only identify 26 carriers correctly but also 100 non-
carriers as carriers [Table 3, bottom]. Thus, a minimal
frequency of ~1 in 100,000 affected individuals for each
listed abnormality was arbitrarily selected in each popula-
tion analyzed to minimize incorrect test results while
maximizing the number of genetic abnormalities identi-
fied. Available patient studies with the largest summarized
experience [1] were selected to compile the abnormal gene
frequencies in populations.
Study setting
The diseases listed in descending order of frequency
were identified from: (1) GeneTests 534 listed disease






















4. Affected adult X X X X
Legend: Carrier screening includes asymptomatic patients selecting partners,
planning to conceive, or pregnant, and partners of identified carriers. Prenatal
testing includes products of conception and at-risk fetuses. Symptomatic newborns
and minors can be tested for autosomal dominant disease loci to determine the
cause of their abnormal phenotype. Adults could be tested for selected late-onset
disease genes and males for Y-linked infertility.the >2500 listed diseases, (2) our 4129 reported products
of conception and prenatal karyotypes in Ohio, (3) our
1265 reported patient microarray results in Texas, and (4)
reanalyzed results of 25,452 prenatally screened women
and their at risk partners tested for 108 disease genes [16].
Type of participants and materials
The abnormal clinically reported prenatal karyotypes
were derived from 1,449 products of conception (POCs),
82 chorionic villus samples, and 2598 amniocenteses
completed at Akron Children’s Hospital from 2002 to
2013 (4,129 total cases). For comparison, we added the
substantially lower frequencies of our previously published
abnormal results on 25,222 amniocenteses and 5,134
chorionic villus samplings with a substantially larger pro-
portion of patients of advanced maternal age among those
cases with abnormal ultrasounds completed by 1992 [21].
The 121 (9.6%) clinically reported abnormal micro-
array results from 1265 Texas’ (T) patients were submit-
ted for phenotypic abnormalities unrelated to oncology.
These 40 different identified submicroscopic deletions
and duplications each spanning about ~2,000,000 base-
pairs were reported with references in the Agilent and/
or BlueGnome databases (Additional file 3: Table S3A,
Ref. [22,23]). The positive results at each genomic locus
were listed initially according to the relative frequency of
each abnormal site observed [Additional file 3: Table S3A,
Col 4, Left]. The frequencies reported in another develop-
mentally delayed population of 15,749 cases and 10,118
controls [24] were added on the right side of the affected
column for comparison [Additional file 3: Table S3A,
Col.4, Right, (K)]. Available reported abnormal copy num-
ber frequencies in the general population were added in
the next column for comparison [Additional file 3: Table
S3A, Col 5].
Table 3 Carrier test accuracies for frequent and rare autosomal recessive diseases [20]
Disease Disease frequency 98% Accurate* 100,000 tested 99.9% Accurate** 100,000 tested Carrier frequency
Cystic Fibrosis ~1/3364 ~3279 Correct ~3445 Correct ~1/29
~2067 Incorrect ~103 Incorrect
(2000 + 67 = 2067) (100 + 3.3 = 103.3)
PKU ~1/10,000 ~1960 Correct ~1998 Correct ~1/50
~2040 Incorrect ~102 Incorrect
(200 + 40 = 2040) (100 + 2 = 102)
Arylsulfatase A ~1/100,000 ~619 Correct ~632 Correct ~1/158
Deficiency ~2012 Incorrect ~101 Incorrect
(2000 + 12.4 = 2012.4) (100 + .6 = 100.6)
Fumarese ~1/60,000,000 ~25 Correct ~26 Correct ~1/3873
Deficiency ~2000 Incorrect ~100 Incorrect
(2000 + .5 = 2000.5) (100 + .026 = 100.026)
*A 96% to 98% accurate cystic fibrosis result frequency was initially reported by CAP certified testing laboratories.
**A 99.5% accurate result frequency was estimated by one commercial microarray manufacturer.
These data illustrate the prudence of testing maternal and fetal samples together.
LEGEND: One first reason for targeting the most frequent genetic diseases is illustrated by the calculated differences between correct and incorrect test results for
diseases with different frequencies given the same test accuracies. For instance, considerably higher test accuracies are observed when calculated for screening of
the more frequent autosomal recessive diseases in unselected asymptomatic carriers. The proportion of incorrectly detected carriers increases substantially for
rare autosomal recessive diseases like Fumarase deficiency.
Clinical test accuracy is optimized during laboratory validation according to College of American Pathology guidelines. An illustrative 98% test accuracy has been
arbitrarily selected for comparison of a Standard of Care test based upon the 96% to 98% accurate cystic fibrosis results reported by CAP certified clinical
laboratories initially screening for the 23 most common cystic fibrosis mutations. Given a test accuracy of 98% for cystic fibrosis would identify ~3279 cystic
fibrosis carriers correctly and ~67 carriers and ~2000 noncarriers incorrectly among 100,000 people. The same test accuracy applied to the rare autosomal
recessive fumarase deficiency with a frequency of ~1 in 60,000,000 would identify 25 of 26 fumarase deficiency carriers correctly but also identify 1 carrier and
~2000 noncarriers incorrectly.
DNA sequencing platforms themselves are anticipated to be substantially more accurate, while entire test accuracy is also modified by sample collection, laboratory
manipulation, and reporting. An arbitrarily selected 99.9% accurate test would decrease the incorrectly identified noncarriers for each genetic disease from ~2000
to ~100 among 100,000 patients tested. At the same time the number of correctly detected cystic fibrosis carriers would increase by 66 to 3445. In contrast, the
26 true carriers of the rare fumarase deficiency with a frequency of 1 in 60,000,000 would be identified correctly among the 100 incorrectly identified carriers.
Compare these to the calculated 99.9% accurate test results for autosomal recessive Arylsulfatase A deficiency with an affected frequency of 1 in 100,000 that
would identify 632 carriers correctly along with 1 carrier and 100 noncarriers incorrectly.
The ~50-fold enriched frequency of most frequent deletions found among all patients submitted for microarray analysis (Additional file 3: Table S3B, top)
illustrates the principle that testing clinically suspicious phenotypes substantially enhances the affected patient frequency among tested samples. Prior screening
test results like hemoglobin electrophoresis for sickle cell anemia and the hemoglobinopathies will further enrich for abnormal patient samples submitted for
DNA analysis.
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with published population frequencies at the top in the
order of chromosomal location for ready comparison
[Additional file 3: Table S3B, top]. The remaining list was
further segregated and ordered according to the chromo-
somal location of frequent deletions and duplications in pa-
tients with altered intellectual development [Additional file
3: Table S3B, middle], followed by patients with other clin-
ical abnormalities [Additional file 3: Table S3B, bottom].
Analysis
All available 534 frequencies reported in the GeneRe-
views chapters under Prevalence were collected in 2011
and updated when a significant change was noted. This
selected disease list is further organized by transmission
category: (A) autosomal recessive, (B) X-linked, and (C)
autosomal dominant [Additional file 1: Table S1A,B,C].
Then Y-linked and mitochondrial diseases were listed
just prior to the frequent diseases in specific populations
[Additional file 1: Table S1D,E,F].Then the abnormal post conception karyotype cat-
egories were listed in order of frequency in products of
conception [Additional file 2: Table S2A, Col 2]. These
included (1) 1449 Products of Conception analyzed from
2002 to 2013 in Ohio, (2) the first 5,134 CVS samples
tested in San Francisco [21] next to the 82 high risk
samples karyotyped in Akron since 2002, (3) the first
21,288 amniocenteses karyotyped in San Francisco [21]
next to the 2,598 karyotyped in Akron since 2002, and
(3) 54,749 newborns karyotyped in Seattle [25].
General population frequencies used in these calculations
include 50% of abnormal karyotyped products of concep-
tion [POC] in Ohio by 2013 and 0.6% of abnormal karyo-
types in newborns in Seattle by 1986 (Additional file 2:
Table S2B, Col 2,5). In contrast, for prenatally sampled
higher risk fetuses, abnormal karyotypes reported in
chorionic villous samplings [CVS] and amniocenteses
completed more recently in Ohio were compared to
those completed by 1992 in San Francisco (Ref. [21];
Additional file 2: Table S2A,B, Columns 3,4).
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[Additional file 3: Table S3A] and their observed and re-
ported frequencies were compiled from several sources:
(1) The clinically reported 40 submicroscopic deletion and
duplication sites each spanning >400,000 basepairs found
in 1265 patients [Additional file 3: Table S3A, Texas (T);
this manuscript], (2) thirteen (13) of the sixteen (16) de-
letions with estimated general population frequencies of
at least 1 in 100,000 selected from GeneTests [Additional
file 3: Table S3B, Top], (3) an additional 23 chromosome
regions reported to result in altered neurocognitive de-
velopment when deleted and occasionally when dupli-
cated [Additional file 3: Table S3B, Middle], and (4) the
additional 12 clinically reported abnormalities identified
among our 1265 constitutional microarrays [Additional
file 3: Table S3B, Bottom]. The first 13 are primarily
syndromic deletions that frequently result in developmen-
tal delay [Additional file 3: Table S3B, Top]. The next
group is reported to result in intellectual delay with or
without other abnormalities. When testing for all these 48
abnormalities in 1265 patients referred for microarrays,
10% were reported positive (T): ~5% in the first 13 loci
[Additional file 3: Table S3B, Top] and ~5% in the
remaining 35 loci [Additional file 3: Table S3B, Middle,
Bottom].
Results
Selection of frequent diseases
The most frequent listed disease locations comprise the
largest proportion of testable disease causing mutations
worldwide. Estimated disease frequencies found in all
tested categories were derived from our calculations
based upon reported patient and general population data
[Additional file 1: Table S1, Additional file 2: Table S2
and Additional file 3: Table S3]. The most frequent disease
alleles for cystic fibrosis and the hemoglobinopathies are
reported to have been selected by heterozygous advantage
[26-28]. In contrast, the other most frequent autosomal
recessive genetic disease genes have many unique alleles
but none were reported to have sufficiently frequent muta-
tions that comprise a major proportion of all mutations
(Additional file 1: Table S1A; Ref. [29]). Thus determining
whether a variant gene sequence is normal at a frequent
disease gene site should include a comparison to all con-
firmed mutations.
Other frequent diseases in ethnic populations result
from a limited founder pool with offspring who regularly
select a partner from among the offspring of all the foun-
ders [Additional file 1: Table S1F]. These ethnic popula-
tions can be tested effectively by targeting the few most
frequent mutations in the founders’ rare disease alleles.
Initially a population disease frequency may be overesti-
mated when sampled from a region with a higher carrier
frequency. Disease frequencies in founder populations canalso skew panethnic population frequencies when off-
spring migrate together to specific geographic regions like
in the United States where more centrally located popula-
tions can more often trace their ancestors to citizens who
arrived earlier in the nation’s history.
The most extensive available disease frequency esti-
mates with the broadest geographical distributions were
found on the GeneTests website in the GeneReviews
chapters. This study considered all the >2500 listed dis-
ease genes [1] for inclusion in at-risk and affected pa-
tient test categories. The disease list selected was further
organized by transmission category: (A) autosomal re-
cessive, (B) X-linked, (C) autosomal dominant, (D) Y-
linked, (E) mitochondrial, and (F) frequent diseases in
specific populations [Additional file 1: Table S1A-F,
Tables 1 and 4]. From the 534 listed and updated Gene-
Tests frequencies, 125 diseases were selected that are each
reported to affect at least 1 in 100,000 Caucasian individ-
uals [Additional file 1: Table S1A,B,C,D] including 122 dis-
eases reported to affect at least 1 in 100,000 people
worldwide [Additional file 1: Table S1A,B,C,D, excluding
#1, 2, 38] and 55 disease genes frequent in specific popula-
tions [Additional file 1: Table S1F].
Additional estimates of disease gene frequencies have
been derived from our tested at-risk and abnormal pa-
tient samples [Additional file 2: Table S2, Col 2.3.4; Add-
itional file 3: Table S3]. Initially the abnormal karyotype
categories are listed according to decreasing frequency
in clinically reported products of conception [Additional
file 2: Table S2A]. These karyotype results were then
reorganized according to estimated severity to facilitate
comparison of the remaining viable karyotypic abnor-
malities as gestation progresses [Additional file 2: Table
S2B]. Calculated general population disease frequencies
include 50% of abnormal karyotyped products of con-
ception [POC] and 0.64% of abnormal karyotypes in
newborns [Additional file 2: Table S2B, Col 2,5, Bottom].
In contrast, for prenatally sampled fetuses tested by
chorionic villus sampling [CVS], abnormal karyotypes
were reported in 3.1% completed by 1992 in San Francisco
[21] compared to 33% completed more recently in Ohio
(Additional file 2: Table S2B, Col 3]). Note also the in-
creased number of abnormal chromosome categories in
the more recent sampled amniocenteses [Additional file 2:
Table S2B, Col 4, Right, underlined).
Then the most frequent 40 aneuploid locations span-
ning >400,000 basepairs characterized by our microar-
rays were organized according to the frequencies of
each abnormality among our 1265 tested patients
[Additional file 3: Table S3A]. These frequencies among
Texas’ patients (T) were subsequently reorganized ac-
cording to chromosome location within 3 categories to
facilitate comparison of (1) the 13 confirmed gene loci
with estimated general population frequencies of at
Table 4 Summary of disease frequencies in total population
Disease category Caucasian Worldwide(f)
(a)Affected (b) Heterozygote (a’) Affected (b’) Heterozygote
A1. Autosomal ~1/668(a) ~2/5 ~1/967 ~1/3
Recessive ~ (0.15%) (~40%) (0.10%) (~34%)
A2. Couples ~ 1/174 ~ 1/255
(~0.58%) (~0.39%)
A3. Late Onset
Parkinson (ww) ~1/120 ~1/3.9* ~1/200 ~1/7
Hemochromatosis (cau) ~ (0.83%) (~26%) (0.5%) (~14%)
B1. X-Linked ~1/1065 ~1/546 ~1/1065 ~1/546
~ (0.094%) (~.18%) ~ (0.094%) (~.18%)
B2. Couples ~1/546 ~1/546
(Recessive) (~.18%) (~.18%)
C. Autosomal ~1/123 ~1/123 ~1/123 ~1/123
Dominant ~(0.81%) (~.81%) ~(0.81%) (~.81%)
D1. Abn POC ~ 1/2 ~1/2 ~1/2 ~1/2
Karyotype ~ (50%) ~ (50%) ~ (50%) ~ (50%)
Quantification (54) ~ (47.7%) ~ (47.7%) ~ (47.7%) ~ (47.7%)
D2. Current Abn Amnio ~ 1/13.8 ~1/13.8 ~1/13.8 ~1/13.8
Karyotype ~ (7.2%) ~ (7.2%) ~ (7.2%) ~ (7.2%)
Quantification (54) ~ (6.1%) ~ (6.1%) ~ (6.1%) ~ (6.1%)
D3. Abnormal Newborn ~1/156 ~1/156 ~1/156 ~1/156
Karyotype ~(0.64%) ~(0.64%) ~(0.64%) ~(0.64%)
Quantification (54) ~(0.59%) ~(0.59%) ~(0.59%) ~(0.59%)
E. Common ~1/1097X 2(e) ~1/1097X 2(e) ~1/1097X 2(e) ~1/1097X 2(e)
Deletions ~(0.18%) (~.18%) ~(0.18%) (~.18%)
F. Y-linked ~1/12,500 ~1/12,500
Hemizygote ~(0.008%) ~(0.008%)
(a) Without late onset hemochromatosis and Parkinson, with cystic fibrosis and α-1-antitrypsin in Caucasians.
(b) E1. First 5 abnormal karyotypes listed in Additional file 1: Table S1E detect 1/329 of 1/184 [.31% of .54%]. Other abnormalities may not be detected with
targeted platform.
(c) E2. Other karyotypic abnormalities that may not be identified by a targeted platform. Lebo et al., 2002, lists additional 30 chromosome regions that would
identify ~97% of all abnormalities if tested for copy number. Platforms with SNPs will identify copy number changes in any region in which these are found.
(d) Adult estimate excludes trisomy 13 and trisomy 18 from category (b) above.
WW =worldwide; Cau = Caucasian.
*Compare to Cystic fibrosis: [1/29]2 X [1/4] =1/3300]. Includes hemochromatosis.
(e) The frequency of the common deletions listed at the top of Additional file 1: Table S1E comprised 5% of the abnormalities identified by microarrays while the
remaining 35 loci at the bottom comprised the other 5%. Thus the first population frequency was multipled by 2 to estimate the total frequency.
(f) Without common regional diseases.
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Right Column, Ref. [1]) (2) the additional reported
chromosome regions that result in altered neurocogni-
tive development with or without other abnormalities
((K); Additional file 3: Table S3B, Col 4; Ref. [24]), and
(3) the remaining 12 abnormal clinically reported loci.
Nearly all frequent deletions listed at the top of Additional
file 3: Table S3B also result in altered developmental delay.
When testing for all these abnormalities, 10% of patients
were reported positive for gene deletion or duplication in
this Texas’ cohort.The frequencies of six disease categories with available
general population frequencies [Additional file 1: Table
S1A,B,C; Additional file 2: Table S2, Newborn; Additional
file 3: Table S3B,Top] were calculated and graphed for
ready interpretation [Figure 1A,B,C]. Note that the largest
proportion of reported disease frequencies is found in the
first subcategory [1/1 to 1/25,000]. These proportions di-
minish rapidly as the affected patient frequency decreases
in increments to [<1/75,000 to 1/100,000]. This consistent
trend can be applied to optimally select disease inclusion



















































































Figure 1 (See legend on next page.)
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Figure 1 Affected disease frequencies in four disease categories in caucasians (A,B,C). The individual contributions of four disease
frequency categories were graphed according to affected total frequencies (percent) for 6 disease categories of surviving patients in increments
of 1 in 25,000. Note the frequencies of the first three categories were graphed with a frequency up to .09% for autosomal recessive, (Additional
file 3: Table S3C), three categories were graphed on different scales with a frequency up to.30% for whole chromosome aneuploidy (Additional
file 3: Table S3E), and autosomal dominant with a frequency up to .75%. 1. Among all the diseases with a frequency of at least 1 in 100,000, 86%
of at-risk couples for an affected fetus with an autosomal recessive disease would be identified by testing only diseases with a frequency up to 1
in 50,000; 2. 91% of at-risk couples for an affected fetus with an X-linked disease would be identified by testing only diseases with a frequency up
to 1 in 50,000; 3. 92% of the patients affected with an auatosomal dominant would be identified by testing only diseases with a frequency up to
1 in 25,000; and 98% with frequencies up to 1 in 50,000; and 4. All frequent duplications and chromosome abnormalities listed have frequencies
exceeding 1 in 25,000. Given that most of these autosomal recessive disease genes have ~50 unique mutations with no particularly common
mutations, [29], decreasing initial screening to diseases with at least 1 in 50,000 will not only substantially reduce the workload but will miss <1
patient per disease category in 2.5 years by a laboratory randomly screening 5,000 normal patients per year. These thresholds may need to be
revised because the abnormal genomic frequencies of affected patients would be substantially greater.
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frequent disease genes according to physician selected or
peer reviewed disease categories will expedite reporting
the largest proportion of clearly positive and negative test
results.
Altogether the first 227 [125 + 54 + 48; Additional file 1:
Table S1, Col.1; Additional file 2: Table S2, Table 5;
Additional file 3: Table S3A] most frequent Caucasian
diseases at 263 loci [227 + 36; See Additional file 1:
Table S1A,B,C,D, Column 4] result from mutations invol-
ving ~1.2% of the ~22,000 human genes [263/22,000 =
1.19%]. This total is 224 diseases for worldwide patients
[122 + 54 + 48]. These values facilitated deriving the fre-
quencies of at-risk asymptomatic couples carrying auto-
somal recessive [Table 4.A.2] and X-linked recessive
diseases (Table 4.B.2) along with the dominant and Y-
linked patient categories [Tables 1 and 4].
Frequent abnormal alleles in populations that are likely
to select a partner from within their own ethnic group
account for virtually all of the remaining homozygous
autosomal recessive affected conceptuses. Altogether
GeneTests reported 55 diseases that each affects at least
1 in 100,000 patients in specific ethnic populations
[Additional file 1: Table S1F]. For the general U.S. popu-
lation, the first five listed ethnicities each comprise at
least 2% of the total U.S. population and together have
31 ethnic specific diseases that can be added readily to
the general population screening test [Additional file 1:
Table S1F, #1-31]. Most ethnic gene mutations require
substantially less effort to test because these typically in-
clude very few frequent abnormal alleles.
The summary of these individual calculated affected
and carrier disease frequencies are listed [Table 4] as
well as the composite rates for Caucasian and World-
wide patient categories [Table 1]. These most frequent
disease lists were constructed to facilitate physician-
selected disease testing that could be ordered for four
patient categories: (1) patients selecting a partner or re-
producing, (2) at-risk conceptuses, (3) abnormal newborns
and minors, and (4) affected adults [Tables 1 and 2].Currently next generation platforms and their modifi-
cations can be used immediately to rapidly sequence the
total exome or ~4800 disease related genetic sites for
pregnant couples and affected newborns and adults. An-
alyzed genes can be selected from among the total re-
sults. Fetuses at a 1 in 4 risk of a known gene defect are
tested for this risk first. Karyotypes are being ordered
initially in Ohio for small invasive prenatal samples, very
late gestation fetuses and 90% of refrigerated POCs that
are cultured and karyotyped. Other facilities order mi-
croarrays [31] for sufficient CVS and amniocyte samples
and up to 40% of POC samples that can not be cultured.
Platforms that complete multiple test categories as well as
the most important fetal test will continue to be developed
and selected from the most reliable source as test plat-
forms evolve and updated databases are constructed and
maintained (Refs. [1,32]; Peer-reviewed publications).
Identifying at-risk couples
Testing asymptomatic patients prior to or during preg-
nancy can determine whether both partners carry the
same recessive disease gene or the female partner car-
ries an X-linked gene conferring a 1 in 4 risk of each
conceptus being affected. Reported population frequen-
cies would identify 40.2% of Caucasians as carriers of
one of the 37 most frequent early onset autosomal reces-
sive diseases [Additional file 1: Table S1A; Table 4.A1.b].
Testing the other current partner will complete the goal
of the screening test by identifying the 1 in 174 asymp-
tomatic couples that both carry the same disease allele
and have a 1 in 4 risk of an affected conceptus [Table 4.
A.2.b]. Simultaneously the ~1 in 546 women [Table 4.
B1.b] would be found who carry 1 of 21 most frequent
X-linked recessive disease alleles with lower female car-
rier frequencies [Additional file 1: Table S1B]. Women
who test positive for one of these genes have a 1 in 4
risk of an abnormal male fetus so that fetal testing
would be offered without testing the partner. Taken to-
gether, ~1 in 132 (.76%) Caucasian couples are at a 1 in
4 risk for one of the first 61 frequent recessive diseases
Table 5 Genetic disease loci in critical chromosome regions
Chromosome
band tested
Gene Disease locus tested Disease frequency OMIM#
1p36.3 MTHFR Homocystinuria due to MTHFR 236250
deficiency 607093
1q44 CIASI FCAS Muckle-wells syndrome N.A. 606416
CINCA syndrome
2p25 TPO Thyroid peroxidase deficiency N.A. 274500
2q37 N.A. UGT1A1 Crigler-Najjar Syndrome, Type II Gilbert Syndrome N.A 606785
3p25-p26 VHL Von Hippel-Lindau Syndrome N.A. 193300
3q27 or TP63 Tumor protein P63 N.A. 603273
3q28 LPP Lipoma-Preferred partner N.A. 600700
4p16.3 or FGFR3 Achondroplasia 1/20,000 100800
4p16.3 HD Huntington Disease 143100
4p35 FSHMD1A Facioscapulohumeral muscular dystrophy 1/250,000 158900
5p15.2-15.3 MSR Methionine Synthase Reductase N.A. 602569
6p25 or FOXC1 Iridogoniodysgenesis N.A. 601090
6p25-p24 F13A1 13coagulation enzyme N.A. 134570
6q27 TBP Spinocerebellar ataxia 17 N.A. 600075
7p22 MAD1L1 Somatic lymphoma N.A. 602686
7q11.2 ELN Williams Syndrome 1/10,000 194050
130160
7q36 PRKAG2 Wolff-Parkinson-White Syndrome N.A. 602743
8p23 or MCPH1 Microcephaly, autosomal N.A. 607117
8p22 LPL recessive 1 1/10,000 238600
Hyperlipoproteinemia I
8q24.3 ZIP4 Acrodermatitis enteropathica N.A. 607059
9p24.2 PDCD1 Mouse model develops lupus* N.A. 605724
9q34.3 AGPAT2 Berardinelli-Seip N.A. 603100
Congenital Lipodystrophy 1
10p15 GATA3 Hypoparathyroidism, sensorineural N.A. 131320
10q26 AOT Ornithine Aminotransferase Deficiency N.A. 258870
11p15.5 CDKNC1 Beckwith-Wiedemann Syndrome N.A. 600856
11q24 KCNJ1 Bartter Syndrome, Type 2 N.A. 600359
12p13.3 VWD Von Willebrand Factor Deficiency 1/20,000 193400
12q24.2 TCF1 Diabetes Mellitus high 142410
Transcription Factor 1
13q34 IRS2 Diabetes Mellitus Insulin receptor substrate 600797
14132.33 IGHM Agammaglobulinemia N.A. 147020
15q11.2 SNRPN # Prader-Willi Syndrome 1/15,000 176270
UBE3A # Angelman Snydrome 1/15,000 601623
15q26.1 RECQL3 Bloom Syndrome N.A. 606410
16p13.3 HBA1 Alpha Thalassemia (C) 141800
41850
16q24.3 FANCA Fanconi Anemia (D) 227650
17p13.3 LIS1 Miller-Dieker Syndrome (E) 90% deletions 247200
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Table 5 Genetic disease loci in critical chromosome regions (Continued)
17p11.2 PMP22 CMT1A/HNPP 1/5,000(F)
20% de novo 162500
17q25.3 HSS Sanfilippo Mucopolysaccharidosis (G) 605270
Type IIIA 252900
18p11.3 TGIF Holoprosencephaly N.A. 602630
18q23 CYB5 Methemoglobinemia N.A. 250790
19p13.3 ELA2 Cyclic Hematopoiesis N.A. 130130
19q13.4 TNNT1 Nemaline myopathy N.A. 191041
20p13 AVP Diabetes Insipidus N.A. 192340
Neurohypophyseal 125700
Arginine Vasopressin
21q22.3 ITGB2 Leukocyte adhesion deficiency N.A. 116920
600065
22q11 DGCR DiGeorge Syndrome N.A. 188400
22q13.3 DIA1 Methemoglobinemia N.A. 250800
Diaphorase deficiency
Xp22.32 STS X-linked ichthyosis 1/5,000 308100
Deletions:
90%
Xp22.32-pter SHOX Short Stature Homeo Box N.A. 604271
312865
Xp21.2 DMD Duchenne Muscular Dystrophy 65% deletions, 7 sites, 90%, 1/3 new mutations 1/4,000 310200
Xq28 SLC6A8 Creatine deficiency syndrome 300352
X-linked 300036
Yp11.3 SRY Sex-determining region Y 480000
Godndal dysgenesis, XY type
Yq11.2 USP9Y Azoospermia 400005
Reproduced from Lebo et al. [30].
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Compare targeted testing to the results of screening
23,453 asymptomatic patients that found 29.2% [24.0%
one allele +5.2% more than one allele] Caucasian and
ethnic carriers of one of 108 rare and frequent recessive
diseases [16]. Testing partners found 1 in 127 couples at
a 1 in 4 risk for an affected fetus with 1 of 18 genetic
diseases among the 108 tested [16]. Our further analysis
found 124 of these 127 at-risk couples in one of two pop-
ulations: (1) 111 of 127 couples at-risk for 1 of 8 frequent
Caucasian diseases (Additional file 1: Table S1A,B); and
(2) 13 of 127 couples at-risk for 1 of 7 ethnic diseases in
couples with ancestors from the same subpopulation
(Table two in Ref. [16]; Additional file 1: Table S1F, This
mss.). Only 3 couples were a risk for 1 of the 91 add-
itional less frequent to rare tested diseases [16].
Subsequently our literature study of each of the 34
most frequent worldwide autosomal recessive geneticdiseases [Additional file 1: Table S1A] found 28 to 652
reported disease causing mutations [29]. In contrast to
cystic fibrosis and the hemoglobinopathies, the 34 world-
wide diseases studied had no common mutant alleles so
that heterozygous carrier advantage did not select for a
few common mutations. Taken together, these comparisons
illustrate the efficacy of selecting the most frequent genetic
diseases identified and testing for all confirmed disease
causing mutations.
Because differences in genetic disease severity or fam-
ily history may modify the couple’s concern about a fetus
affected with a reported disease [33], letters a, b, or c
have been for more to less severe diseases [Additional
file 1: Table S1A, 1–37] Discovering a 1 in 4 risk of an
affected fetus for an autosomal recessive disease carried by
both partners has modified mate selection. Discovering a
1 in 4 risk of an affected fetus for either an autosomal re-
cessive or X-linked disease enables a couple to select other
reproductive options prior to or during pregnancy or to
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fetus, simultaneously testing parental samples including
any new partners provides optimal controls to further
confirm the fetal test result and maintain test accuracy.
Reporting only abnormal prenatal results based only on
previously reported disease causing genotypes substan-
tially simplifies writing the most accurate reports, counsel-
ing, and a couple’s decision.
Products of conception and prenatal screening
Akron Children’s product of conception [POC] protocol
includes a pathologist’s examination, description, biopsy,
histology, and submission of freshly biopsied chorionic
villi for karyotyping. Chorionic villus biopsies are preferred
to other fetal tissues because 90% of viable submitted fetal
samples maintain cell viability when refrigerated up to
5 days prior to cell culture or DNA analysis compared to
the poorer viability of other fetal tissues. Histologically
prepared villi are analyzed for mole and partial mole
morphology (Additional file 4: Table S4). The cytogenetics
laboratory assures dissection of the villi to 90-95% purity
for karyotyping and 98-100% purity for molecular ana-
lyses. After digestion and culturing, chorionic villus cells
from 90% of submitted placental samples have been karyo-
typed. (Additional file 2: Table S2A). Following a prelimin-
ary report, polymorphic DNA identity testing confirms
the fetal origin of the cultured samples prior to a final re-
port. Of the remaining 10% of failed cultures, 7% are suffi-
ciently intact to analyze interphase nuclei by FISH for
chromosome 13, 16, 18, 21, 22, X, and Y aneuploidy com-
prising ~63% of all chromosome abnormalities in our kar-
yotyped POCs. These 50% of cultures with abnormal
reported karyotypes among all karyotyped POCs are listed
in order of frequency for each category [Additional file 2:
Table S2A, Col 2]. Given the 90% of samples karyotyped,
these abnormal frequencies are interpreted to reflect typ-
ical POC population frequencies. ACOG recommends
using microarrays for POC samples when 20%-50% of
samples fail to grow in cuture and cannot be karyotyped
[34]. Given 90% of our POCs are karyotyped according to
our protocol, we have karyotyped all cultured POCs to
identify tetraploidy from diploid genomes and balanced or
complex categories of chromosome abnormalities currently
missed by microarrays and genomewide sequencing.
Sampled at-risk fetuses have been karyotyped follow-
ing CVS or amniocentesis to serve as the clinically
standard test for microscopically visible chromosome ab-
normalities. For comparison we added the most recent
12 years of prenatal karyotypes in Ohio to our published
25 years of prenatal karyotypes in San Francisco from
1970 to 1995. This comparison found a 10.6-fold increase
in more recent abnormal CVS karyotypes [3.1% to 33%]
and a 3.2-fold increase in more recent abnormal amnio-
cyte karyotypes (2.3% to 7.2%; Ref. [21]; Additional file 2:Table S2A, Col 3,4) These substantially higher abnormal
frequencies in Akron’s more recent samples are consistent
with those published recently by the American College of
Obstetrics and Gynecology [34].
Subsequently these results were organized by severity
to emphasize the evolution of surviving abnormal karyo-
types as the time after conception increases [Additional
file 2: Table S2B)]. These POC frequencies were com-
pared to the reported frequencies in CVS, amniocen-
tesis, and newborn karyotypes (Additional file 2: Table
S2B, Col 2,3,4,5; Ref. [21]). Additional categories were
observed in POC specimens: (1) triploid to aneuploid,(2)
tetraploid to aneuploid, and (3) aneuploid to tetraploid
[Additional file 2: Table S2B Col 2, Top, Underlined].
Additional categories were also observed in the more re-
cent amniocyte samples over those previously published:
(1) double aneuploidy, (2) isochromosomes, (3) complex
abnormalities with two or more abnormal chromosome
categories, (4) diploid to tetraploid, (5) trisomy 16 and
22, (6) monosomy 11 and 21, and (7) mosaic karyotypes
[Additional file 2: Table S2B, Col 4, Underlined, Italicized].
The 54 selected sites reported to comprise the most
frequent chromosome regions involved in abnormal
chromosome copy number (Table 5, Reproduced from
Ref. [30]; Derived from [32]) were found to have identi-
fied all the abnormal chromosome copy number regions
identified in the listed abnormal POC, CVS, and amnio-
cyte karyotypes in Akron [Additional file 2: Table S2B].
Because 2,500,000 site polymorphic microarrays only de-
tect abnormal copy number, the frequency of abnormal-
ity detection would not have been increased by this
assay, but the chromosome region spanned by the copy
number change would have been delineated. These ab-
normal 54 aneuploid loci can be identified on any plat-
form that (1) detects a sufficient number of the most
informative adjacent single, di- and tetra-nucleotide
polymorphisms and quantifies the relative and total
number of times each of these sites were sequenced or
(2) the relative number of targets at the aneuploid site
compared to a normal diploid control region. Candidate
platforms include rapid sequencers and microarrays. Fol-
lowing initial identification of an aneuploid chromo-
somal gene region on a 54 site test, the extent of the
aneuploid gene region could be delineated readily by
completing a typical polymorphic genomewide micro-
array or a ~4800 disease gene sequence.
Targeting these 54 sites can readily serve as the next
generation screening test of circulating placental DNA in
maternal circulation [cfDNA] to enable genomewide
aneuploid chromosome analysis. These 54 sites com-
prising the most frequent microscopically visible aneu-
ploid chromosome regions would include sufficiently large
genomic targets to compare many polymorphic sites for
small differences contributed by fetal DNA. The results
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tests are anticipated to continue to be more accurate than
prior screening tests. Assuring that reported posterior test
accuracy is reported correctly will enable the most
confident initial and subsequent screening test utilization.
Alternative platforms and karyotyping should be com-
pared carefully for different applications as tests evolve.
For instance, among the ~50% of karyotypically abnormal
POC samples, ~45% of these abnormal samples would
have been detected by either a 54 site or a 2,500,000 site
genomewide test platform provided the control DNA in-
cludes an intact Y chromosome [Additional file 2: Table
S2B, not italicized]. The same platforms would have de-
fined copy number changes in 5.7% of the 7.2% [(79%);
(7.2%-1.54%)] abnormal amniocyte karyotypes and in
~25.7% of the 33% [(78%); (33%-7.3%)] current abnormal
CVS karyotypes [Additional file 2: Table S2B].
Compare this to microarrays with 2,500,000 sites that
precisely map unknown and previously detected unbal-
anced rearrangements and submicroscopic aneuploidy.
These extensive microarrays are particularly useful in
delineating the 6% of inherited cases with undetected
submicroscopic deletions or duplications not detected
in karyotypes of a conceptus with an apparently bal-
anced chromosomal rearrangement inherited from a
normal carrier parent [35]. In spite of the propensity of
unequal chromosome recombinations among the po-
tentially confounding ~2,370,000 copy number variants
[3,36], balanced rearrangements are beginning to be de-
tected by improved genomewide platforms and sophisti-
cated computer analysis [17,37]. Karyotyping is the only
means to detect diploid to tetraploid mosaicism and tetra-
ploidy arising from diploid cells. As microarray, sequen-
cing, and flow sorting methods for detecting balanced
abnormalities are being validated in additional patients
with substantial analytic resources,[17] standard karyotyp-
ing is still the preferred method for detecting balanced
and complex rearrangements in a few viable cells.
Selecting the most optimal platform for any individual
fetus will depend upon available ongoing test deveopment
and available protocols through referral laboratories. At our
location we karyotype all CVS samples because of the 33%
found to have abnormal karyotypes. Currently we karyotype
amniocytes for substantially abnormal ultrasounds and se-
lect the fetal samples to be sent for microarray analysis fol-
lowing following rapid FISH overnight. Our first sample
designated for microarray testing was positive for trisomy
21 by Rapid FISH and subsequent karyotyping.
Symptomatic newborns and children
Pediatricians following standard of care can decide to test
symptomatic newborns and children for all frequent gen-
etic disease categories that may define the abnormal
phenotype. These disease categories include the autosomaldominant diseases resulting in ~1 in 123 affected new-
borns [Additional file 1: Table S1C, Table 4C] and the fre-
quent deletions and duplications causing an estimated ~1
in 549 affected newborns [1/1097 X 2; Additional file 3:
Table S3A,B, Table 4E]. Together these and all previously
mentioned genetic disease categories [Table 1.3] result in
~1 in 54 [1.86%] affected newborns worldwide and 1 in 52
[1.91%] Caucasian newborns.
Calculated dominant disease prevalence reflects a dis-
ease frequency that includes many heterozygous abnor-
mal genotypes [2pq] and very few homozygous affected
patients [q2] in randomly mating populations with re-
producing patients. Mutations involving 60 of these fre-
quent autosomal dominant diseases [Additional file 1:
Table S1C, Table 4C] include a substantial proportion
that resulted from de novo mutations [2% to 95%]. As
anticipated, these de novo autosomal dominant muta-
tions are often more severe than autosomal dominant
diseases inherited from reproducing adults. If an auto-
somal dominant disease gene were identified in an af-
fected minor, parents could then be counseled and
offered testing to determine whether the minor’s disease
gene is de novo [including parental germ line and som-
atic mosaicism], or resulted from substantial anticipa-
tion, variable penetrance, or variable expressivity.
Testing these autosomal dominant diseases requires a
platform with the sensitivity to detect single nucleotide
mutations.
The submicroscopic deletion and duplication category
was addressed by analyzing the prior 5 years of ab-
normal microarray results that each spanned >400,000
basepairs in our Texas’ patient cohort. These samples
were submitted in order of highest to lowest frequency
by Neonatologists, Pediatric Neurologists, Geneticists,
Developmentalists, and Pediatricians. The 9.6% abnor-
mal results [121/1265] were organized into three cat-
egories [Additional file 3: Table S3B]: (1) 13 loci with
frequent deletions with reported normal and abnormal
population frequencies that nearly all involved altered
neurocognitive development [Additional file 3: Table
S3B, Top], (2) at least 23 additional reported loci related
to altered neurocognitive development with reported fre-
quencies in abnormal patients [Additional file 3: Table
S3B, Middle], and (3) 12 additional clinically significant
loci including three chromosomal abnormalities. [Add-
itional file 3: Table S3B, Bottom] About 1/2 of the 123
total deletions and duplications spanned 9 of the first 13
recurrent deletion loci. The other ~1/2 of the cases in
categories 2 and 3 included 8 recurrent schizophrenia
loci [24,38].
A 52-fold enrichment was found between the 1 in 21
affected patients selected for microarray testing in
Texas and an estimated 1 in 1097 patients predicted in
the general population by estimated disease frequencies
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frequency of most frequent deletions found among all pa-
tients submitted for microarray analysis illustrates the
principle that testing clinically suspicious phenotypes sub-
stantially enhances the affected patient frequency among
tested samples [Additional file 2: Table S2 and Additional
file 3: Table S3]. Although a chromosome abnormality was
not suspected, 15 cases with trisomy 21, trisomy 18, or iso
(12p) were identified by microarrays in our Texas cohort.
Given the difficulty in identifying the exact genetic abnor-
mality by the patient phenotype alone, selected karyotyp-
ing may be prudent.
Symptomatic adults
Symptomatic adults can be tested for all disease categories
mentioned previously as well as late onset genetic diseases
following appropriate counseling and informed consent.
These diseases include Parkinson’s disease, Alzheimer dis-
ease, and amyotrophic lateral sclerosis in worldwide popu-
lations and Huntington disease in Caucasians.
Frequent diseases in specific populations
The 52 genetic diseases reported to be most frequent in
specific populations listed in GeneTests have been incor-
porated to expedite optimal disease testing in regional
laboratories (Additional file 1: Table S1F). Israeli labora-
tories will want to incorporate platforms with the most
frequent Jewish mutations where 6,000,000 Israeli Jews
reside, while laboratories in Sweden and Norway would
include the Nordic mutations, labs in Quebec the French
Canadian mutations, and Asian labs their regionally re-
ported mutations. Worldwide, subpopulations of citizens
within specific populations that typically select partners
from their own ethnic groups would readily be served by
incorporating the few frequent mutations for these dis-
eases into the population wide screening test. These in-
clude Asian, Black, and Jewish United States citizens
that each comprise at least 2% of the entire pan ethnic
United States population (Additional file 1: Table S1F
Group 3; Ref. [39]) and regional laboratories in central
Pennsylvania, northeast Ohio, and Colorado where
200,000 Amish and Mennonite regional residents [0.08%
of the total panethnic population] carry >50 specific gene
mutations reported in these descendents of a few score of
founders.
Targeting frequent disease loci enriches clearly defined
reportable results
Currently interpreting genomewide exome sequencing
of all ~22,000 genes requires several times the cost of se-
quencing. Dr. Hruban reported “a human exome has on
average almost 36,000 variants, 45 percent of which are
not in an SNP database and about 100 of which can
cause loss of function” [40]. He concluded, “Thepotential power of next-generation sequencing for clin-
ical testing is substantial. It will be a while before it is
brought fully to the clinic…” This agrees with Chun
et al. who identified ~90 potential disease causing se-
quences identified by exome analysis of all ~22,000
genes in three individuals [5]. When testing 100,000 pa-
tients for the frequent autosomal recessive cystic fibrosis
mutations with 99.9% test accuracy per gene, a positive
carrier test would include 3445 correct answers and 103
incorrect answers (Table 3, Top; Ref. [20]). In contrast,
for the rare fumarase deficiency gene locus with the
same test accuracy a positive carrier test would not only
include 26 correctly analyzed carriers but also 100 incor-
rect false positive carrier test results [Table 3, Bottom].
Maintaining the principle of testing the most frequent
diseases listed from most to less frequent in each se-
lected category provides an objective basis to select the
lowest frequency of any tested disease in each category.
Discussion
In summary. analyzing the 227 diseases affecting 263
loci that are each reported to affect at least 1 in 100,000
Caucasian individuals together include ~1.2% of all the
22,000 gene loci [~1 in 84], and ~9.1% [~1 in 11] of the
>2500 listed clinically testable disease causing genes [1].
Based upon these frequencies, analyzing all >2500
known disease causing genes is estimated to identify ~11
potential disease causing genes. In contrast, testing the
attached list of most frequent 227 disease loci in
the United States [Additional file 1: Table S1, Additional
file 2: Table S2 and Additional file 3: Table S3] is antici-
pated to decrease the number of candidate affected geno-
types to be considered to ~0-2 per patient. This list of
frequent diseases includes ~7 of 8 of McKusick’s
(1982) estimated single locus Caucasian birth defects
{[1.91/ (0.4% + 1.8%) = 87%] Table 1.3a, Ref. [41]} and ~6 of
7 Worldwide birth defects without region specific testing.
[Derived from McKusick’s estimated 1.8% transmitted by
Mendelian inheritance plus 0.4% chromosome abnormal-
ities]. These most frequent diseases affect about 1 in 52
Caucasian newborns and 1 in 54 worldwide [Table 1.3.a,a’]
These listed sites [Additional file 1: Table S1, Additional
file 2: Table S2 and Additional file 3: Table S3] focus test-
ing to the fewest most informative disease gene locations
to achieve the highest possible test accuracy (Table 3; Refs.
[20,42]). Because abnormal phenotypes are frequently seen
in more than one genetic disease or chromosome abnor-
mality, this targeted genomewide patient category testing
approach can readily identify suspected and unsuspected
abnormalities too numerous to test individually.
The 54 targeted chromosomal sites that would have
identified all the microscopically visible aneuploid
chromosome regions in our reported karyotypes reflect
the efficacy of targeting the most frequent disease
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ome sequencing identify nearly all Genomewide normal
and abnormal modifications. Genomewide platforms
and computer programs can now be targeted to analyze
only the most frequent disease causing sites [Additional
file 1: Table S1, Additional file 2: Table S2 and Add-
itional file 3: Table S3]. Platforms and computer pro-
grams that reveal physician selected patient categories
and the diseases to be included will further enhance la-
boratory turnaround time [Figure 1A,B,C; Table 1]. Any
selected platform category is likely to determine copy
number. Upon further modification, rapid sequencing
platforms and/or polymorphic or sequencing microar-
rays are anticipated to enable analyzing the most fre-
quent reported disease causing mutations at fewer
tested sites to most efficiently utilize all manufacturing,
testing, interpretation, and counseling resources. Report-
ing only peer reviewed published mutations with their ref-
erences would enable actionable results while minimizing
inconclusive test risks.
The 13 frequent deletions reported in ~1 in 21 of the
patients tested by microarrays were ~52-fold more fre-
quent in this physician selected population than in the
general population [1 in 1097; Additional file 3: Table
S3B, Top)]. Although the relative contribution of each
submitted patient category will be modified according to
the physician’s specialty, substantial enrichment of ab-
normal genotypes is anticipated in all affected patient
categories submitted for testing. This will improve upon
total test accuracy.
Given the use and analysis of large genome data in
clouds, companies are offering sufficient computing
capability to analyze and store genomewide sequencing
data for subsequent reanalysis. Given multiple reanaly-
ses could be applied to the same data set as additional
disease genes are discovered, disease gene mutations
are cataloged, and new clinical information becomes
available, stored genomewide data can be reanalyzed
without resequencing. Laboratories that choose to pro-
vide this service can write additional programs to
analyze all the data and distribute summaries of new
findings to contributing physicians. All this requires
prior patient understanding and agreement to receive
updated information by continuing these analyses. The
Perspective by Dr. Pyeritz addresses possible legal im-
plications of reporting or of not reporting newly discov-
ered genes [43]. Ongoing modifications to maintain
optimal test platforms can be based upon additional
identified disease genes, a change in individual observed
disease frequency in sampled affected patients, ongoing
test results, the geographical origin(s) of tested patients,
and additional published causative mutations.
The U.S. Army Corps of Engineers Motto is, “The dif-
ficult we do immediately. The impossible takes a littlelonger”. Computer programs that reveal only physician
selected gene results on the core panel can immediately
optimize patient specific testing and minimize laboratory
liability for unreported loci. Targeting and testing the
most frequent genetic abnormalities on a single platform
[Additional file 1: Table S1 A-G] will identify most clin-
ically meaningful abnormal genotypes for any designated
patient category. Testing all the confirmed disease asso-
ciated genes with the most frequent disease core would
provide ~10-fold less data than the total disease causing
exome platform. The following applications can be con-
sidered immediately:
1. Testing the 54 most frequent chromosomal sites
to identify most microscopically visible karyotypic
abnormalities in fetal DNA in maternal
circulation.
2. Targeting less than 64 frequent worldwide genomic
abnormalities in the core list [Additional file 1:
Table S1A,B] to readily identify the largest
proportion of couples at-risk for affected fetuses
worldwide.
3. Targeting ~257 listed genomic sites (Additional file
1: Table S1A-E) would identify most known genetic
disease-causing mutations in abnormal children.
4. Developing targeted genomewide testing for the
most frequent abnormalities including both single
nucleotide mutations and gene aneuploidy on a
single platform (Additional file 1: Table S1,
Additional file 2: Table S2 and Additional file 3:
Table S3) to optimize genomewide testing.
5. Computer programs written to only reveal each
physician selected patient category and genes within
it on any genomewide panel enables targeted testing
with the fewest platforms.
6. Adding population-specific frequent disease
mutations according to a testing laboratory’s
geographical location.
Conclusion
This principle of selecting and testing the most frequent
genomewide disease causing abnormalities in ~1 of 8
known disease loci (1 of 84 total gene loci) is estimated
to identify the genetic defect in ~7 of 8 reported ab-
normal newborn Caucasians. In contrast, this would
eliminate ~8 to10 of ~10 Caucasian newborn gene se-
quences selected as abnormal that are actually normal
variants identified when testing all ~4800 reported dis-
ease genes to search for the remaining 1 of 8 disease
causing genes. Adopting this approach will minimize
incorrect results while optimizing test accuracy, coun-
seling, and reimbursement for a larger proportion of
appropriate patients within available laboratory and re-
imbursement resources.
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